Provided by Tiger Trade Technology Pte. Ltd.

Pfizer

27.63
-0.1550-0.56%
Volume:22.65M
Turnover:623.19M
Market Cap:157.07B
PE:36.35
High:27.75
Open:27.75
Low:27.40
Close:27.78
52wk High:29.21
52wk Low:23.58
Shares:5.69B
Float Shares:5.64B
Volume Ratio:0.75
T/O Rate:0.40%
Dividend:1.72
Dividend Rate:6.23%
EPS(TTM):0.7599
EPS(LYR):1.36
ROE:5.01%
ROA:5.78%
PB:1.84
PE(LYR):20.25

Loading ...

Stray Alert from NYSE Tagged to Multiple Companies Withdrawn

Reuters
·
Aug 04

Dow Jones Top Company Headlines at 9 am ET: McDonald's Aims to Improve Service and Food, and Chose a New U.S. Boss to Help | Pfizer's ...

Dow Jones
·
Aug 04

Pfizer Edges up After Better-than-Expected Quarterly Results

Reuters
·
Aug 04

Coherent, Palantir, SpaceX, Caterpillar, Pfizer, and More Stocks That Explain Today's Market

Dow Jones
·
Aug 04

Pfizer's Quarterly Results Beat Expectations on Cancer, Heart Drugs

Dow Jones
·
Aug 04

Pfizer's Mixed Q2 Results: Oncology Gains Offset COVID Revenue Declines

Deep News
·
Aug 04

Pfizer Stock (PFE) Flat on 2026 Sales Outlook as Cancer Drugs Fuel Q2 Beat

TIPRANKS
·
Aug 04

Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis

Bloomberg
·
Aug 04

Pfizer: in 2026, NOW Expect Unfavorable Revenue Impact from Patent-Based or Regulatory Exclusivity Expiries of Approximately $1.1 Bln- SEC Filing

THOMSON REUTERS
·
Aug 04

Pfizer Logs Mixed 2Q on Oncology Growth, Covid-19 Declines

Dow Jones
·
Aug 04

Why Pfizer Stock and This Covid Vaccine Partner are Falling on Earnings

Dow Jones
·
Aug 04

Pfizer Q2 Adjusted Earnings Decline, Revenue Increases; 2026 Revenue Outlook Narrowed

MT Newswires Live
·
Aug 04

Pfizer reports Q2 adjusted EPS 77c, consensus 68c

TIPRANKS
·
Aug 04

Pfizer backs FY26 adjusted EPS view $2.80-$3.00, consensus $2.95

TIPRANKS
·
Aug 04

Pfizer announces expansion of productivity enhancement Initiatives

TIPRANKS
·
Aug 04

Pfizer Beats Earnings Estimates, Targets $2.5 Billion in Additional Cost Cuts

Reuters
·
Aug 04

Pfizer Says Q2 2026 Results Beat Expectations on Non-COVID Brand Growth and Cost Discipline

Reuters
·
Aug 04

Pfizer- Plan to Advance Phase 3 Program for Berobenatide That Includes 10 Studies for Chronic Weight Management, Obesity-Related Conditions This Year

THOMSON REUTERS
·
Aug 04

Pfizer - Aim Delivering Risk-Adjusted High Single-Digit Revenue Cagr from Year-End 2028 Through Year-End 2033- Prepared Remarks

THOMSON REUTERS
·
Aug 04

Pfizer: Expect a Pivotal Trial Start This Year Investigating Nurtec’s Use as a Treatment for Chronic Migraine- Prepared Remarks

THOMSON REUTERS
·
Aug 04